Compare Spotify Technology (SPOT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs BIO-TECHNE Corp — how do they compare? Spotify Technology trades at $500.5 (market cap $105.22B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Spotify Technology is far larger — about 9.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| SPOT | TECH | |
|---|---|---|
Market Cap | $105.22B | $11.24B |
Sector | Media | Health |
52-Week High | $738.53 | $72.29 |
52-Week Low | $412.75 | $43.31 |
Enterprise Value | $94.91B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $488.14, up 2.75% with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with Q2 2026 revenue growth of 14% year-over-year and record gross margins of 33.4%, though earnings missed expectations due to increased marketing and AI costs. Premium subscribers surpassed 300 million for the first time, supporting the long-term growth narrative.
Wall Street maintains a bullish outlook with 61.5% buy ratings and a $598.20 consensus price target representing 22.5% upside potential. Key risks include execution on AI investments, competitive pressure in streaming, and margin sustainability. The stock presents growth opportunity if monetization initiatives succeed.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
